Chris Garabedian

Chris Garabedian serves as Chairman and CEO of Xontogeny since June 2016 and has been a Portfolio Manager for the PXV Fund at Perceptive Advisors since May 2017. In addition, Chris holds board member positions at AsclepiX Therapeutics, CereVasc, and Zucara Therapeutics, all since 2020. Previously, Chris was Chairman of the Board for Landos Biopharma until May 2024 and served as Chairman of the Board at Forge Biologics until December 2023. A Senior Advisor to the Healthcare Practice at The Boston Consulting Group from January 2016 to December 2021, Chris has also held the role of Chairman of the Board at Quellis Biosciences and served as Chief Executive Officer at Sarepta Therapeutics from January 2011 to March 2015. Chris Garabedian earned a B.S. in Marketing from the University of Maryland between 1985 and 1989.